参芪扶正注射液联合化疗治疗晚期胃癌临床观察

目的观察比较参芪扶正注射液联合DCF（多西紫杉醇＋顺铂＋5-氟尿嘧啶）方案与单纯DCF方案治疗转移性或复发性晚期胃癌的疗效及毒副反应。方法将经病理组织学及影像学确诊为转移性或复发性晚期胃癌患者50例作为研究对象,随机分为参芪扶正注射液联合DCF方案组（联合治疗组）26例及单纯DCF方案组（对照组）24例。每例患者每治疗2个周期,进行疗效评价。结果联合治疗组可评价疗效26例：完全缓解（CR）0例,部分缓解（PR）12例,稳定（SD）9例,总有效率为46.2%;对照组可评价疗效24例：CR 0例,PR 10例,SD 8例,总有效率为41.7%;两组疗效比较差异无统计学意义（P〉0.05）。联合治疗组生活质量Karnofsky评分总有效率为76.9%;对照组为50.0%,差异有统计学意义（P〈0.05）。联合治疗组白细胞减少的发生率（76.9%）、恶心呕吐发生率（76.9%）显著少于对照组白细胞减少的发生率（95.8%）及恶心呕吐发生率（95.8%）,差异有统计学意义（P〈0.05）。结论参芪扶正注射液能够减少DCF方案化疗毒副作用,增加患者化疗耐受性,提高生活质量。

Clinical observation of Shenqifuzheng Injection in combination with chemotherapy in the treatment of patients with advanced gastric carcinoma

Objective To observe and compare the efficacies and toxicities of Shenqifuzheng Injection combined with DCF regimen（Docetaxel ＋ Cisplatin ＋ 5-Fluorouracil） and DCF regimen alone in the treatment of patients with advanced gastric carcinoma.Methods 50 patients with advanced gastric carcinoma,diagnosed by histopathology and imaging,were randomly divided into 26 cases of Shenqifuzheng Injection combined with DCF group（combination treatment group） and 24 cases of DCF regimen alone group（control group）.Each patient took the evaluation of efficacy after receiving at least 2 cycles of treatments.Results 26 cases could be evaluated in combination treatment group and 24 cases could be evaluated in control group.In combination treatment group,there were 0 case of CR,12 cases of PR,9 cases of SD,the overall response rate was 46.2%.In control group,there were 0 case of CR,10 cases of PR,8 cases of SD,the overall response rate was 41.7%.The difference of the overall response rates between the two groups was insignificant（P 0.05）.The increase rate of Karnofsky score for the quality of life（76.9%） in combination treatment group was significantly higher than that in control group（50.0%）（P 0.05）.The incidence rates of leucopenia and gastrointestinal reactions in combination treatment group were 76.9% and 76.9%.These incidence rates were significantly lower than those in the control group（95.8%,95.8%）（P 0.05）.Conclusion Shenqifuzheng Injection can attenuate toxic effects of DCF chemotherapy.And it can enhance patients＇ tolerance to chemotherapy and improve the quality of patients＇ life.